3 results
The primary objective of this study is to determine if there is an improvement in progression-free survival(PFS) when siltuximab is added to VELCADE* (bortezomib) and dexamethasone in subjects with relapsedor refractory multiple myeloma.The…
The aim is to determine on the basis of the results of this study whether there is measurable effect on the ability to drive after long term use of ICADTS class III drugs. To achieve this goal drugs will be tested out of the groups most commonly…
This study is an open-label, non-randomized extension to study CCDZ173X2201. It aims to provide treatment with CDZ173 to patients withAPDS/PASLI who participated in study CCDZ173X2201 or who were treated previously with PI3Kδ inhibitors other than…